Axsome Therapeutics has not undergone a corporate buyout or acquisition by a larger pharmaceutical conglomerate; it operates as an independent, publicly traded biopharmaceutical company listed on the Nasdaq exchange under the ticker symbol AXSM. Management continues to execute its commercial growth strategy independently, focusing on expanding the market adoption of its flagship central nervous system medications, advancing late-stage clinical pipeline candidates, and driving shareholder value through organic commercialization rather than an acquisition.